Published in Neurology on September 19, 2007
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
B cells in multiple sclerosis: connecting the dots. Curr Opin Immunol (2011) 1.45
The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS One (2010) 1.32
The evidence for a role of B cells in multiple sclerosis. Neurology (2012) 1.32
IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. PLoS One (2009) 1.25
Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol (2010) 1.17
The radiologically isolated syndrome: take action when the unexpected is uncovered? J Neurol (2010) 1.09
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol (2015) 1.04
The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol (2013) 1.01
Lipocalin 2 is present in the EAE brain and is modulated by natalizumab. Front Cell Neurosci (2012) 1.01
Immunomodulatory treatment strategies in multiple sclerosis. J Neurol (2008) 0.99
Biomarkers in Multiple Sclerosis: An Up-to-Date Overview. Mult Scler Int (2013) 0.93
Cerebrospinal fluid in multiple sclerosis. Ann Indian Acad Neurol (2009) 0.93
Optimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America. Ther Adv Neurol Disord (2011) 0.92
Evolving expectations around early management of multiple sclerosis. Ther Adv Neurol Disord (2010) 0.91
Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis. J Neuroimmunol (2011) 0.91
Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. Brain (2015) 0.90
In multiple sclerosis, oligoclonal bands connect to peripheral B-cell responses. Ann Neurol (2014) 0.89
Oligoclonal bands and MRI in clinically isolated syndromes: predicting conversion time to multiple sclerosis. J Neurol (2010) 0.89
Idiopathic acute transverse myelitis: outcome and conversion to multiple sclerosis in a large series. BMC Neurol (2013) 0.88
Retinal nerve fibre layer thinning in patients with clinically isolated optic neuritis and early treatment with interferon-beta. PLoS One (2012) 0.87
Clinically isolated syndromes suggestive of multiple sclerosis: an optical coherence tomography study. PLoS One (2012) 0.87
Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study. PLoS One (2012) 0.86
CSF abnormalities can be predicted by VEP and MRI pathology in the examination of optic neuritis. J Neurol (2012) 0.85
Symptomatic paroxysmal dysarthria-ataxia in demyelinating diseases. J Neurol (2010) 0.84
Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis. PLoS One (2014) 0.84
Assessing the value of spinal cord lesions in predicting development of multiple sclerosis in patients with clinically isolated syndromes. J Neurol (2011) 0.83
Kappa free light chains: diagnostic and prognostic relevance in MS and CIS. PLoS One (2014) 0.83
A prospective study of patients with brain MRI showing incidental t2 hyperintensities addressed as multiple sclerosis: a lot of work to do before treating. Neurol Ther (2014) 0.82
The antibody genetics of multiple sclerosis: comparing next-generation sequencing to sanger sequencing. Front Neurol (2014) 0.81
Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis. Mult Scler (2011) 0.80
Event time analysis of longitudinal neuroimage data. Neuroimage (2014) 0.80
MRI criteria in MS patients with negative and positive oligoclonal bands: equal fulfillment of Barkhof's criteria but different lesion patterns. J Neurol (2009) 0.79
B cells contribute to MS pathogenesis through antibody-dependent and antibody-independent mechanisms. Biologics (2012) 0.79
Proteomic analysis of cerebrospinal fluid for relapsing-remitting multiple sclerosis and clinically isolated syndrome. Biomed Rep (2016) 0.79
Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis. Neurohospitalist (2013) 0.78
CSF analysis in suspected MS: do bands aid? Neurology (2008) 0.78
Predicting outcome in clinically isolated syndrome using machine learning. Neuroimage Clin (2014) 0.78
Validation of semaphorin 7A and ala-β-his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis. J Neuroinflammation (2014) 0.78
Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome. J Neurol (2016) 0.78
The presence of oligoclonal IgG bands in human CSF during the course of neurological diseases. J Neurol (2014) 0.77
Neurofilament light chain level is a weak risk factor for the development of MS. Neurology (2016) 0.77
Protein-Based Classifier to Predict Conversion from Clinically Isolated Syndrome to Multiple Sclerosis. Mol Cell Proteomics (2015) 0.77
McDonald Criteria 2010 and 2005 Compared: Persistence of High Oligoclonal Band Prevalence Despite Almost Doubled Diagnostic Sensitivity. Int J Mol Sci (2016) 0.76
Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis. PLoS One (2017) 0.75
Serum biomarker gMS-Classifier2: predicting conversion to clinically definite multiple sclerosis. PLoS One (2013) 0.75
Free Light Chains and Intrathecal B Cells Activity in Multiple Sclerosis: A Prospective Study and Meta-Analysis. Mult Scler Int (2016) 0.75
Quantified CSF antibody reactivity against myelin in multiple sclerosis. Ann Clin Transl Neurol (2015) 0.75
Clinically Isolated Syndromes: Clinical Characteristics, Differential Diagnosis, and Management. Noro Psikiyatr Ars (2015) 0.75
Oligoclonal Bands in Cerebrospinal Fluid of Black Patients with Multiple Sclerosis. Biomed Res Int (2015) 0.75
Cerebrospinal fluid humoral immunity in the differential diagnosis of multiple sclerosis. PLoS One (2017) 0.75
Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study. PLoS One (2017) 0.75
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology (2005) 3.45
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
MR imaging findings in 56 patients with Wernicke encephalopathy: nonalcoholics may differ from alcoholics. AJNR Am J Neuroradiol (2008) 2.76
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology (2009) 2.58
Correlation of the highest-energy cosmic rays with nearby extragalactic objects. Science (2007) 2.57
Prognostic significance of blood pressure variability after thrombolysis in acute stroke. Neurology (2008) 2.45
EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol (2010) 2.45
The development of low-grade cerebral edema in cirrhosis is supported by the evolution of (1)H-magnetic resonance abnormalities after liver transplantation. J Hepatol (2001) 2.42
Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol (2000) 2.10
Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler (2012) 2.07
New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology (2003) 2.04
[Effectiveness of smoking cessation intervention in patients with cardiovascular disease]. Rev Esp Cardiol (2001) 1.93
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol (2011) 1.93
MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90
Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology (2009) 1.78
Cosmetic sequelae after conservative treatment for breast cancer: classification and results of surgical correction. Ann Plast Surg (1998) 1.72
Pituitary enlargement in patients with intracranial hypotension syndrome. Neurology (2000) 1.71
A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain (2009) 1.69
Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol (2000) 1.66
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler (2009) 1.65
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol (2008) 1.63
Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Neurology (2008) 1.62
Lumbar extradural hemangiomas: report of three cases. AJNR Am J Neuroradiol (1999) 1.55
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
[Neurologic manifestations of varicella herpes zoster infection]. Enferm Infecc Microbiol Clin (1995) 1.49
Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler (2009) 1.49
Measurement of the depth of maximum of extensive air showers above 10{18} eV. Phys Rev Lett (2010) 1.48
New anatomical classification of the axilla with implications for sentinel node biopsy. Br J Surg (2010) 1.46
Antiviral immune response in patients with multiple sclerosis and healthy siblings. Mult Scler (2010) 1.44
Plasma chitotriosidase activity in multiple sclerosis. Clin Immunol (2009) 1.44
[Adnexal masses management: a prospective multicentric observational study]. Gynecol Obstet Fertil (2008) 1.42
Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology (2006) 1.42
Towards a european network for multiple sclerosis trials (ENMST). Mult Scler (2003) 1.40
Sleep-disordered breathing and upper-airway anomalies in first-degree relatives of ALTE children. Pediatr Res (2001) 1.40
Genetic association of CASP8 polymorphisms with primary progressive multiple sclerosis. J Neuroimmunol (2010) 1.40
Bayesian analysis of pentaquark signals from CLAS data. Phys Rev Lett (2008) 1.39
[Descriptive study of first visits in a multiple sclerosis specialised unit]. Neurologia (2002) 1.39
[Body mass index influence in the insulin action mechanisms]. An Med Interna (1998) 1.38
[The development of multiple sclerosis following an isolated episode of optic neuritis. Magnetic resonance study]. Med Clin (Barc) (1997) 1.37
Measurement of two- and three-nucleon short-range correlation probabilities in nuclei. Phys Rev Lett (2006) 1.37
Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS? Mult Scler (2005) 1.36
Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann Oncol (2011) 1.33
Can the Expanded Disability Status Scale be assessed by telephone? Mult Scler (2003) 1.28
Prospective evaluation of late cosmetic results following breast reconstruction: I. Implant reconstruction. Plast Reconstr Surg (2001) 1.27
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology (2010) 1.27
Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer (2005) 1.26
Role of magnetic resonance imaging within diagnostic criteria for multiple sclerosis. Ann Neurol (2004) 1.25
Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction. Clin Cancer Res (2000) 1.24
The autoimmune disease-associated KIF5A, CD226 and SH2B3 gene variants confer susceptibility for multiple sclerosis. Genes Immun (2010) 1.22
Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. Brain (1999) 1.22
Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler (2008) 1.21
Gray and white matter volume changes in early RRMS: a 2-year longitudinal study. Neurology (2005) 1.20
EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol (2005) 1.20
In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. J Antimicrob Chemother (1999) 1.18
A care bundle approach for prevention of ventilator-associated pneumonia. Clin Microbiol Infect (2012) 1.17
Nondrug treatment trials in psychophysiologic insomnia. Arch Intern Med (1995) 1.16
Complications of lymphadenectomy for gynecologic cancer. Eur J Surg Oncol (2012) 1.14
High lipoprotein (a), diabetes, and the extent of symptomatic intracranial atherosclerosis. Neurology (2004) 1.13
MRI findings in Möbius syndrome: correlation with clinical features. Neurology (2000) 1.13
Distribution territories and causative mechanisms of ischemic stroke. Eur Radiol (2005) 1.12
Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocr Relat Cancer (2006) 1.11
Conservative treatment of breast cancers by mammaplasty and irradiation: a new approach to lower quadrant tumors. Plast Reconstr Surg (1995) 1.11
mTOR signalling in human cancer. Clin Transl Oncol (2007) 1.09
Neuromyelitis optica diagnosis in clinically isolated syndromes suggestive of multiple sclerosis. Neurology (2006) 1.09